- Home
- NXB vs IBIO Comparison
NXB vs IBIO Comparison
Compare NXB & IBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NXB | IBIO |
|---|---|---|
| Founded | 2012 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.2M | 52.8M |
| IPO Year | 2025 | 2009 |
Fundamental Metrics
Financial Performance| Metric | NXB | IBIO |
|---|---|---|
| Price | $1.45 | $0.76 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $5.69 |
| AVG Volume (30 Days) | 38.9K | ★ 828.6K |
| Earning Date | 11-21-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 81.71 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $119,866,298.00 | N/A |
| Revenue This Year | $41.82 | N/A |
| Revenue Next Year | $29.41 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 21.08 | N/A |
| 52 Week Low | $1.40 | $0.69 |
| 52 Week High | $2.57 | $3.82 |
Technical Indicators
Market Signals| Indicator | NXB | IBIO |
|---|---|---|
| Relative Strength Index (RSI) | 29.04 | 34.69 |
| Support Level | N/A | $0.73 |
| Resistance Level | $2.36 | $1.52 |
| Average True Range (ATR) | 0.13 | 0.07 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 29.11 | 35.51 |
Price Performance
Historical ComparisonAbout NXB NextBoat Inc. Common Stcok
NextBoat Inc focused on AI-powered technology platform designed to modernize and scale the world-wide pre-owned marine marketplace.
About IBIO iBio Inc.
iBio Inc is a clinical-stage biotechnology company using Artificial Intelligence (AI) for the development of hard-to-drug precision antibodies for obesity, cardiometabolic, and cardiopulmonary diseases. Its product candidate pipeline includes IBIO-610, a monoclonal antibody designed to block Activin E; IBIO-800, a bispecific antibody program targeting myostatin, growth differentiation factor 11 (GDF11), and Activin A; IBIO-600; Amylin Antibody; and Target 4, in different stages of development, being developed as potential therapies for obesity and cardiometabolic disease. The company operates as one reportable segment, which is that of a biotechnology company leveraging AI and ML for the development of hard-to-drug precision antibodies.